We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDNL
RNS Number : 4845T
Diurnal Group PLC
13 October 2017
13 October 2017
Diurnal Group plc
("Diurnal" or the "Company")
Posting of Annual Report and AGM Notice
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that its Annual Report and Accounts for the year ending 30 June 2017, together with the notice of Annual General Meeting (AGM), have today been posted to shareholders.
The documents are being made available at the investor relations section of the Company's website, www.diurnal.co.uk.
The Company's AGM will be held at 11.30am at the offices of FTI Consulting LLP, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD on Tuesday 21 November 2017.
For further information, please visit www.diurnal.co.uk or contact: +44 (0)20 3727 Diurnal Group plc 1000 Martin Whitaker, Chief Executive Officer Richard Bungay, Chief Financial Officer Numis Securities Ltd (Nominated +44 (0)20 7260 Adviser) 1000 Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield Corporate Broking: James Black Panmure Gordon (UK) Limited (Joint +44 (0) 20 7886 Broker) 2500 Corporate Finance: Freddy Crossley / Duncan Monteith Corporate Broking: Tom Salvesen +44 (0)20 3727 FTI Consulting 1000 Simon Conway Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBSBDGIXBBGRD
(END) Dow Jones Newswires
October 13, 2017 04:00 ET (08:00 GMT)
1 Year Diurnal Chart |
1 Month Diurnal Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions